Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2025-08-10 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
公司章程（2025年8月）
Governance Information Classification · 100% confidence The document is a detailed company charter or articles of association (章程) for 赛隆药业集团股份有限公司, covering company governance, shareholder rights, board structure, share issuance, meetings, and other corporate governance matters. It is not a financial report, earnings release, or announcement. It is a governance document outlining internal rules and procedures. Therefore, it fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance provisions, not just an announcement or summary.
2025-08-10 Chinese
《董事会议事规则》（2025年8月）
Governance Information Classification · 95% confidence The document is titled "赛隆药业集团股份有限公司 董事会议事规则" which translates to "Sailong Pharmaceutical Group Co., Ltd. Board Meeting Rules." The content details the rules and procedures for the company's board of directors meetings, including composition, powers, meeting convocations, voting procedures, and record-keeping. It references relevant laws and company bylaws but does not contain financial data, audit results, or report summaries. It is a governance document outlining internal board rules rather than a report or announcement of financial results or management changes. Therefore, it fits the category of Governance Information (CGR). The document length is 5398 characters, sufficient for a detailed governance report, not a brief announcement.
2025-08-10 Chinese
《董事会审计委员会工作细则》（2025年8月）
Governance Information Classification · 95% confidence The document is titled as the "Board Audit Committee Working Rules" of a company, detailing the structure, responsibilities, and procedures of the audit committee within the board of directors. It focuses on governance, internal controls, audit supervision, and committee operations rather than presenting financial data or audit results. There is no indication that this is an audit report, annual report, or any financial statement. Instead, it is a governance document outlining internal rules and committee functions. Therefore, it fits best under Governance Information (CGR). The document length is sufficient and it is not a brief announcement or certification, so it is not RPA or RNS.
2025-08-10 Chinese
关于参加最近一次独立董事培训的承诺书（张凯）
Board/Management Information Classification · 95% confidence The document is a commitment letter from an independent director candidate regarding participation in a required training program recognized by the Shenzhen Stock Exchange. It is a formal declaration related to board governance and director qualifications, not a financial report, announcement of voting results, or any other regulatory filing type. It pertains to board/management information about director candidacy and compliance with governance requirements. Therefore, the most appropriate classification is Board/Management Information (MANG). The document is very short and does not contain financial data or meeting results, so other categories are not applicable.
2025-08-10 Chinese
独立董事候选人声明与承诺（张建民）
Board/Management Information Classification · 95% confidence The document is a detailed declaration and commitment statement by an independent director candidate for a company's board. It includes statements of compliance with various legal and regulatory requirements for independent directors, qualifications, and commitments to fulfill duties. There are no financial statements, earnings data, or report summaries. It is not an announcement of a report publication but a formal declaration related to board/management information. This fits the category of Board/Management Information (MANG), as it concerns the nomination and qualifications of a board member.
2025-08-10 Chinese
第四届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the tenth meeting of the fourth board of directors of Sailong Pharmaceutical Group Co., Ltd. It includes information about board member resignations, nominations, and appointments, as well as amendments to company bylaws and meeting rules. The document also mentions that these resolutions will be submitted to the upcoming extraordinary general meeting for approval. There is no financial data or report content, but rather it focuses on board and management changes and governance matters. Therefore, this document fits best under the category of Board/Management Information (MANG). The document length is 3186 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2025-08-10 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.